FDA Expands Regulatory Framework to Streamline Digital Therapeutic Approvals for Chronic Conditions

The FDA released updated guidance in May 2024 that refines how software functions for chronic disease management are classified under medical device rules. The changes expand the set of low-risk software categories while tightening expectations for clinical evidence on higher-risk tools. This matters because it directly affects which digital products reach patients with conditions such as diabetes or heart disease and how their performance is monitored after launch.

Regulatory definitions and scope

The revised policy distinguishes software functions that support general wellness from those that meet the definition of a medical device. Low-risk wellness tools remain outside active FDA oversight when they do not diagnose or treat specific diseases. In contrast, software that influences clinical decisions for chronic conditions is subject to device regulations.

The Clinical Decision Support guidance from 2022 continues to require manufacturers to demonstrate that their tools provide reliable outputs for patient management. Updated language in the 2024 documents adds detail on interoperability and data exchange standards that affect chronic care platforms.

Clinical evaluation expectations

Manufacturers must now supply stronger evidence of safety and effectiveness for software used in ongoing disease management. Real-world data from post-market use is highlighted as a key input for these evaluations. The agency notes that evidence requirements scale with the level of risk the software presents to users.

Post-market monitoring

The FDA has increased emphasis on surveillance after software reaches the market. Developers are expected to track performance metrics and report issues that could affect chronic condition outcomes. Real-world evidence collected through routine use can support continued clearance or trigger additional review.

What this means

The updates narrow the boundary between regulated and unregulated digital tools while raising the bar for evidence on products that guide treatment decisions. Developers gain clearer criteria for exemption, yet those building decision-support functions face more structured data requirements. Patients may encounter a wider range of low-risk wellness apps alongside more rigorously reviewed therapeutic software.

Key takeaways

• The FDA clarified risk categories for digital health software in guidance dated May 31, 2024, expanding low-risk exemptions for certain chronic disease functions [1].
• Clinical evidence standards for decision-support software remain anchored in the 2022 guidance and now stress real-world performance data [2].
• Post-market surveillance and ongoing evidence collection are positioned as central to regulatory oversight of software as a medical device [3].
• The framework prioritizes higher-risk applications while reducing review burden on lower-risk wellness tools.
• Guidance documents reflect the agency's current position and may shift as new evidence and technologies emerge.

Limitations

The guidance represents the FDA's current position but may evolve further as the digital health landscape and evidence base expand. Guidance documents are non-binding and should be interpreted in context with statutory and regulatory requirements. Developers must assess applicability to their specific products, and international alignment is ongoing but not fully harmonized.

Last updated: September 2, 2026